Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer

NCT02151721 is registered in ClinicalTrials.gov with Kanazawa University as lead sponsor.

NCT NCT02151721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02151721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer
Lead sponsor
Kanazawa University
Phase
Phase 1
Overall status
Unknown status
Start date
June 1, 2014
Completion date
February 20, 2018
Enrollment
12 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma